Showing results (2781-2790 of 6,517) with videos related to

Sort By:
Pageof 652
Cancer Immunology, Immunotherapy : CII|December 19, 2020
The immunologic tumor microenvironment in endometrioid endometrial cancer in the morphomolecular context: mutual correlations and prognostic impact depending on molecular alterationsBarbara Willvonseder, Fabian Stögbauer, Katja Steiger, et al.
Cancer Immunology, Immunotherapy : CII|November 12, 2020
Induction of cytotoxic effector cells towards cholangiocellular, pancreatic, and colorectal tumor cells by activation of the immune checkpoint CD40/CD40L on dendritic cellsFarsaneh Sadeghlar, Annabelle Vogt, Raphael U Mohr, et al.
Cancer Immunology, Immunotherapy : CII|July 8, 2021
Pre-pembrolizumab neutrophil-to-lymphocyte ratio (NLR) predicts the efficacy of second-line pembrolizumab treatment in urothelial cancer regardless of the pre-chemo NLRTakashi Kobayashi, Katsuhiro Ito, Takahiro Kojima, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1985
Evaluation of circulating immune complexes in lymphomas and leukemias using two different assaysG V Patel, R Gopal, J J Nadkarni
Cancer Immunology, Immunotherapy : CII|January 1, 1985
Tumor cells do not arise frequentlyW Den Otter
Cancer Immunology, Immunotherapy : CII|January 1, 1985
Regulation of leukocyte glass adherence and tube leukocyte adherence inhibition (LAI) reactivity by serum factors in dogs with progressing or spontaneously regressing canine transmissible venereal sarcoma (CTVS)M W Harding, T J Yang
Cancer Immunology, Immunotherapy : CII|October 30, 2020
Impact of tumor heterogeneity and microenvironment in identifying neoantigens in a patient with ovarian cancerTao Dao, Martin G Klatt, Tatyana Korontsvit, et al.
Cancer Immunology, Immunotherapy : CII|November 1, 2020
Noninvasive, longitudinal imaging-based analysis of body adipose tissue and water composition in a melanoma mouse model and in immune checkpoint inhibitor-treated metastatic melanoma patientsWolfgang M Thaiss, Sergios Gatidis, Tina Sartorius, et al.
Cancer Immunology, Immunotherapy : CII|November 1, 2020
SAKK 19/17: safety analysis of first-line durvalumab in patients with PD-L1 positive, advanced nonsmall cell lung cancer and a performance status of 2Michael Mark, Patrizia Froesch, Eric Innocents Eboulet, et al.
Cancer Immunology, Immunotherapy : CII|October 18, 2020
Efficacy and safety of sintilimab in combination with chemotherapy in previously untreated advanced or metastatic nonsquamous or squamous NSCLC: two cohorts of an open-label, phase 1b studyHaiping Jiang, Yulong Zheng, Jiong Qian, et al.
Pageof 652